DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Taste Assessment of BMS-986165 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: Active Pharmaceutical Ingredient

First Posted Date: 2018-11-23

Last Posted Date: 2019-10-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT03751228

Locations: 🇺🇸
Senopsys, Woburn, Massachusetts, United States

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Biological: NKTR-214
Biological: Nivolumab

First Posted Date: 2018-11-19

Last Posted Date: 2021-10-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3

Registration Number: NCT03745807

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165

First Posted Date: 2018-11-14

Last Posted Date: 2021-02-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT03739788

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

Completed

Conditions: Melanoma

Interventions: Other: Non-Interventional

First Posted Date: 2018-11-06

Last Posted Date: 2022-12-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 600

Registration Number: NCT03732560

Locations: 🇺🇸
Local Institution, Parsippany, New Jersey, United States

An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

Phase 2

Completed

Conditions: Myocardial Failure
Congestive Heart Failure
Heart Decompensation
Cardiac Failure

Interventions: Drug: BMS-986231
Drug: Furosemide
Drug: Placebo

First Posted Date: 2018-11-05

Last Posted Date: 2021-02-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 23

Registration Number: NCT03730961

Locations: 🇬🇧
Richmond Pharmacology, London, United Kingdom
🇬🇧
Glasgow Clinical Research Facility, Glasgow, United Kingdom

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Phase 2

Active, not recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy
Non-obstructive Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy

Interventions: Drug: mavacamten

First Posted Date: 2018-10-29

Last Posted Date: 2024-03-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 282

Registration Number: NCT03723655

Locations: 🇮🇱
Local Institution - 0023, Safed, Israel
🇵🇹
Local Institution - 0036, Almada, Portugal
🇮🇱
Local Institution - 0022, Ramat-gan, Israel

and more 65 locations

A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2018-10-22

Last Posted Date: 2021-01-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 140

Registration Number: NCT03714022

Locations: 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
PPD Development, LP, Austin, Texas, United States

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986278
Drug: Rifampin

First Posted Date: 2018-10-19

Last Posted Date: 2019-06-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT03712540

Locations: 🇺🇸
PRA Health Science KK, Lenexa, Kansas, United States

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 2

Withdrawn

Conditions: Cancer of the Stomach
Stomach Cancer
Gastric Cancer
Gastroesophageal Junction

Interventions: Biological: Relatlimab + Nivolumab
Biological: Nivolumab
Drug: Ramucirumab
Drug: Paclitaxel

First Posted Date: 2018-10-12

Last Posted Date: 2020-05-19

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03704077

Locations: 🇪🇸
Local Institution, Valencia, Spain

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986177
Other: Placebo (for BMS-986177)
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2018-10-09

Last Posted Date: 2021-09-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 113

Registration Number: NCT03698513

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy